Please login to the form below

Not currently logged in
Email:
Password:

Realm Therapeutics appoints Sandy Zweifach as non-executive director

But Matthew Hammond and Daniel Hegglin retire

Biopharmaceutical company Realm Therapeutics has appointed Sandy Zweifach as a new non-executive director following the retirement of Matthew Hammond and Daniel Hegglin, both of whom served as non-executive directors.

Zweifach joins the biopharma with over 25 years’ experience in the life science industry, with a background in corporate partnering, business development, operations, private and public investing and capital raising.

He is founder, president and chief executive officer of Nuvelution Pharma, a company facilitating the clinical advancement of late stage pharmaceutical and biotechnology assets via a research and development risk-sharing approach that deploys capital and human resources.

Prior to this, Zweifach has served in several leadership roles, including CEO of Ascendancy Healthcare, CEO and president of Pathway Diagnostics and president and CFO of Epoch Biosciences.

Alex Martin, chief executive officer, Realm Therapeutics, said: “I am excited to welcome Sandy to the board.

“His background and experience in both the biopharmaceutical industry and investment banking will be helpful as we progress our pipeline and expand our optionality in 2018 and beyond.”

23rd November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics